Follow one topic of conversation at a time
Canukinumab and FMFView: Translations (EN) Original language
In Turkey and Israel, Novartis is starting to test Canukinumab (Ilaris) with Colchicine resistant FMF patients.
Canukinumab is already being used as a treatment for another auto-inflammatory rare disease, CAPS disorders.
See the trial information here:
and here for pediatric cases in Israel: